<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890173</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-A-J301</org_study_id>
    <nct_id>NCT02890173</nct_id>
  </id_info>
  <brief_title>Study of CS-3150 in Patients With Essential Hypertension</brief_title>
  <acronym>ESAX-HTN</acronym>
  <official_title>A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients
      with essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg
      compared to Eplerenone in patients with essential hypertension.

      Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg
      compared to 2.5 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">July 11, 2017</completion_date>
  <primary_completion_date type="Actual">July 11, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitting blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Change from baseline in sitting systolic (SBP) and diastolic blood pressure (DBP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24 hour average blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Change from baseline in 24 hour average systolic and diastolic blood pressure.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1001</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-3150 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 5 mg, orally, once daily after breakfast for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_label>CS-3150 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 20 years or older at informed consent

          -  Subjects with essential hypertension satisfying the following blood pressure criteria;

               -  Sitting SBP: ≥ 140 mmHg and &lt; 180 mmHg

               -  Sitting DBP: ≥ 90 mmHg and &lt; 110 mmHg

               -  Mean 24 hr BP: SBP ≥ 130 and DBP ≥ 80 mmHg

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Diabetic nephropathy or diabetes mellitus with albuminuria

          -  Serum potassium level &lt; 3.5 or ≥ 5.1 mEq/L

          -  Reversed day-night life cycle including overnight workers

          -  eGFR &lt; 60 mL/min/1.73 m^2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>Mineralocorticoid receptor antagonist</keyword>
  <keyword>Esaxerenone</keyword>
  <keyword>Ambulatory blood pressure monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

